Table 1.
Characteristics of acenocoumarol users with an INR of 6.0 or greater and total cohort
| Patients with INR ≥6.0 (n = 887) | Total cohort (n = 2755) | HR* | 95% CI | |
|---|---|---|---|---|
| Gender | ||||
| Male (%) | 405 (45.7) | 1192 (43.3) | 1.00 | Reference |
| Female (%) | 482 (54.3) | 1563 (56.7) | 1.25 | (1.15, 1.36) |
| Start age (years) | ||||
| 45–54 | 10 (1.1%) | 114 (4.2%) | 1.00 | Reference |
| 55–64 | 72 (8.1%) | 383 (14.0%) | 2.89 | 1.75, 4.78 |
| 65–74 | 214 (24.1%) | 907 (33.2%) | 2.74 | 1.69, 4.45 |
| 75–84 | 389 (43.9%) | 998 (36.5%) | 4.14 | 2.56, 6.68 |
| >85 | 202 (22.8%) | 334 (12.2%) | 6.10 | 2.63, 14.1 |
| BMI (kg m−2) | ||||
| 15.0–20.0 | 17 (1.9) | 45 (1.6) | 1.00 | Reference |
| 20.1–25.0 | 228 (25.7) | 718 (26.1) | 0.70 | 0.52, 0.93 |
| 25.1–30.0 | 492 (55.5) | 1446 (52.6) | 0.68 | 0.51, 0.91 |
| >30.0 | 150 (16.9) | 539 (19.6) | 0.56 | 0.42, 0.76 |
| Target level (INR) | ||||
| 2.0–2.5 | 1 (0.1) | 118 (4.3) | 1.00 | Reference |
| 2.0–3.5 | 389 (43.9%) | 1728 (62.7%) | 10.1 | 3.23, 31.2 |
| 3.0–4.0 | 482 (54.3%) | 889 (32.3%) | 27.9 | 9.00, 86.7 |
| 3.5–4.5 | 15 (1.7%) | 20 (0.7%) | 65.4 | 17.3, 247 |
| Subjects with NSAID use | 89 (10.0) | 470 (17.0) | 1.31 | 1.15, 1.50 |
| Subjects with PPI use | 198 (22.3) | 862 (31.3) | 1.46 | 1.31, 1.64 |
| CYP2C9 genotypes† | n = 648 (73.1% of all cases) | n = 2083 (75.6% of the total group) | ||
| CC | 428 (66.0%) | 1346 (64.6%) | 1.00 | Reference |
| CT | 192 (29.6%) | 659 (31.6)% | 1.03 | 0.92, 1.15 |
| TT | 28 (4.3%) | 78 (3.7%) | 1.49 | 1.20, 1.85 |
| CYP2C9 wild type genotype vs. variant alleles | n = 648 (73.1% of all cases) | n = 2083 (75.6% of the total group) | ||
| CC | 428 (66.0%) | 1346 (64.6%) | 1.00 | Reference |
| CT or TT | 220 (34%) | 737 (35.4%) | 1.09 | 0.98, 1.20 |
*
Univariate analysis of HR was performed with the Andersen-Gill model. HRs cannot be calculated with the numbers in this table because controls may later become cases; significant values are printed in bold.
†
For the CY2C9 genotype within total cohort, allelic frequency of the C-allele was 80.9%, of the T-allele 19.1%, and HWE was 0.96. INR, international normalized ratio; HR, hazard ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.